TAM
IOVA icon

Tyers Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Tyers Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$16K Sell
880
-154
-15% -$3.41K ﹤0.01% 963
2019
Q2 		$25K Hold
1,034
– – ﹤0.01% 953
2019
Q1 		$10K Sell
1,034
-110
-10% -$1.07K ﹤0.01% 972
2018
Q4 		$10K Buy
+1,144
New +$11K ﹤0.01% 938

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tyers Asset Management's IOVA Position: Q3 2019 in Review

Tyers Asset Management reduced its Iovance Biotherapeutics (IOVA) stake by 15% in Q3 2019, selling an estimated $3.41K and leaving 880 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #963.

Tyers Asset Management first reported a position in IOVA in Q4 2018 and has held it in 4 quarters since. The position peaked at $25K in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Tyers Asset Management held 880 shares of Iovance Biotherapeutics worth $16K as of Q3 2019.
  • Tyers Asset Management sold 154 Iovance Biotherapeutics shares in Q3 2019, an estimated $3.41K.
  • Iovance Biotherapeutics made up ﹤0.01% of Tyers Asset Management's portfolio in Q3 2019, its #963 holding.
  • Tyers Asset Management first reported a position in Iovance Biotherapeutics in Q4 2018 and has held it in 4 quarters since.
  • Tyers Asset Management's Iovance Biotherapeutics position peaked at $25K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Tyers Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.